Guided by the results above and existing evidence from literature on genes with relevance in AML, we further selected GPR56 and IGF1R for further in vitro validation of the impact on cytarabine resistance in AML cell lines. The gene discussed is IGF1R; the disease is acute myeloid leukemia.